SCHEDULE: Weiner Jeffrey David Discloses 5.07% Stake in PSYENCE BIOMEDICAL
Beneficial Ownership Report
Jeffrey David Weiner has reported a beneficial ownership of 5.07% of PSYENCE BIOMEDICAL LTD.'s Common Shares.
Summary
- Jeffrey David Weiner has filed a Schedule 13G, indicating beneficial ownership of 51,850 Common Shares of PSYENCE BIOMEDICAL LTD.
- This ownership represents 5.07% of the total class of securities.
- Weiner Jeffrey David holds sole voting power and sole dispositive power over all 51,850 shares.
- The filing certifies that the securities were not acquired for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it is a standard regulatory disclosure of beneficial ownership and does not contain performance or strategic updates.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Management Comments
- "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."
Industry Context
StockSavvy.ai notes that Schedule 13G filings are routine disclosures for passive investors who acquire more than 5% of a company's shares, indicating a significant, non-controlling stake. Such filings provide transparency regarding major shareholders and can sometimes signal investor confidence or interest in a particular sector, though this specific filing does not provide further context on industry trends.
Stakeholder Impact
- Shareholders: The disclosure of a new significant shareholder provides transparency regarding the company's ownership structure.
Key Dates
| Date | Description |
|---|---|
| 02/13/2026 | Date of event which requires filing of this statement |
| 02/18/2026 | Signature date of the Schedule 13G filing |
Keywords
PSYENCE BIOMEDICAL LTD., Common Shares, Beneficial Ownership, Schedule 13G, Shareholder, Investment, Equity
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.